Lung Adenocarcinoma Pipeline: 25+ Companies Advancing Targeted Therapies and Immuno-Oncology Redefining Treatment | DelveInsight

The treatment landscape for lung adenocarcinoma, a leading form of non-small cell lung cancer (NSCLC), is undergoing a significant transformation. Once limited to traditional chemotherapy and radiation, advancements in targeted therapies and immuno-oncology are offering new hope for patients. The focus has shifted from general symptom management to precision medicine, with an emphasis on targeting specific molecular drivers and immune checkpoints. With the increasing understanding of tumor genetics and immune evasion mechanisms, new drug candidates are emerging, including tyrosine kinase inhibitors (TKIs), immune checkpoint inhibitors, and targeted therapies against specific mutations like EGFR, ALK, and ROS1.

DelveInsight's "Lung Adenocarcinoma - Pipeline Insight, 2025" offers a comprehensive analysis of the global R&D landscape, covering both clinical and preclinical-stage drugs with novel mechanisms of action. The report highlights promising therapies such as next-generation EGFR inhibitors, MET inhibitors, ALK inhibitors, and novel immune modulators. Additionally, it provides insights into the growing role of combination therapies, personalized treatment strategies, biomarkers for patient stratification, and regulatory incentives that are accelerating the pace of innovation. Companies leading these developments include BerGenBio, Innovent Biologics, Lantern Pharma, Celltrion, Pionyr Immunotherapeutics, Onconova Therapeutics, and Pfizer, among others. With lung adenocarcinoma being a major global health concern, this report captures the emerging treatment paradigms that are reshaping its management and offering potential for improved patient outcomes.

Interested in learning more about the current treatment landscape and the key drivers shaping the lung adenocarcinoma pipeline? Click here: https://www.delveinsight.com/report-store/lung-adenocarcinoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Key Takeaways from the Lung Adenocarcinoma Pipeline Report
• DelveInsight's lung adenocarcinoma pipeline analysis depicts a strong space with 25+ active players working to develop 25+ pipeline drugs for lung adenocarcinoma treatment.
• The leading lung adenocarcinoma companies include BerGenBio, Innovent Biologics, Lantern Pharma, Celltrion, Pionyr Immunotherapeutics, Onconova Therapeutics, Pfizer, Chugai Pharmaceutical, Novartis Oncology, Alaunos Therapeutics, Tmunity Therapeutics, Imugene Limited, Hoffmann-La Roche, Cantargia, and others are evaluating their lead assets to improve the lung adenocarcinoma treatment landscape.
• Key lung adenocarcinoma pipeline therapies in various stages of development include Belapectin, GXHPC 1, LPCN 1148, Cellgram-LC, BIV-201, Ornithine phenylacetate, CILO, TQA 3526, Saroglitazar, LDE225, Elafibranor, OP-724, BMS 986263, CNP-104, HTD 1801, ASC42, and others.
• In May 2025, Lantern Pharma Inc. (Nasdaq: LTRN) announced that the FDA approved an amendment to its IND application, allowing the start of a Phase Ib/II clinical trial for LP-184 in a genomically defined NSCLC patient population to improve outcomes.
• In March 2025, Boan Biotechnology (06955.HK) announced that its targeted CD228 antibody-drug conjugate, BA1302, received orphan drug designation (ODD) from the FDA for squamous non-small cell lung cancer and pancreatic cancer.
• In March 2025, Johnson & Johnson announced that new data from its oncology pipeline, including overall survival results from the Phase III MARIPOSA study, will be presented at the 2025 European Lung Cancer Congress. The study evaluates RYBREVANT® (amivantamab-vmjw) plus LAZCLUZETM (lazertinib) versus osimertinib in first-line treatment for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR exon 19 deletions or L858R mutations.
• In February 2025, the FDA granted Fast Track designation to IBI363, a first-in-class PD-1/IL-2α-bias bispecific antibody fusion protein, for treating patients with unresectable, locally advanced, or metastatic squamous NSCLC that has progressed after anti-PD-(L)1 therapy and platinum-based chemotherapy.
• In January 2025, the FDA accepted and granted priority review to the BLA for Dato-DXd for adult patients with locally advanced or metastatic EGFR-mutated NSCLC who have previously received systemic therapies, including EGFR-targeted treatments. This BLA is supported by findings from the phase II TROPION-Lung05 trial, phase III TROPION-Lung01 trial, and phase I TROPION-PanTumor01 trial.
• In January 2025, the FDA granted fast-track designation to BBO-8520 for adult patients with previously treated KRAS G12C-mutated metastatic NSCLC. BBO-8520 is an investigational oral agent being evaluated in an open-label, multicenter, first-in-human phase I study for the treatment of KRAS G12C-mutated NSCLC and colorectal cancer (CRC).
• In December 2024, the FDA granted accelerated approval to BIZENGRI, the first systemic therapy for NSCLC or pancreatic adenocarcinoma (PDAC) with an NRG1 gene fusion.

Request a sample and discover the recent breakthroughs happening in the lung adenocarcinoma pipeline landscape at https://www.delveinsight.com/report-store/lung-adenocarcinoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Lung Adenocarcinoma Overview
Lung adenocarcinoma is the most prevalent type of primary lung cancer in the United States and is classified as a subtype of non-small cell lung cancer (NSCLC). It is closely linked to a history of smoking, though it is also the most commonly diagnosed lung cancer in non-smokers. Representing about 40% of all lung cancers, adenocarcinoma typically originates from mucosal glands in the lung periphery, often found in areas of chronic inflammation or scarring.

While both the incidence and mortality rates of lung adenocarcinoma have decreased, it remains the leading cause of cancer-related deaths in the U.S. Smoking is the primary risk factor, with exposure to carcinogens in tobacco smoke increasing the likelihood of developing the disease. Other risk factors include a family history of lung cancer and exposure to environmental toxins like silica, asbestos, radon, heavy metals, and diesel fumes, although these are less common. Genetic mutations, particularly in the p53 gene, are found in 52% of NSCLC cases and are a key driver of tumor development.

Find out more about lung adenocarcinoma medication at https://www.delveinsight.com/report-store/lung-adenocarcinoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Lung Adenocarcinoma Treatment Analysis: Drug Profile
Bemcentinib: BerGenBio
Bemcentinib is a first-in-class, oral, selective inhibitor of AXL receptor tyrosine kinase, taken once daily. AXL is a key player in cancer progression, promoting tumor growth, metastasis, survival, and resistance to therapy. It also facilitates viral entry and replication within host cells. Bemcentinib is currently in Phase II clinical trials for the treatment of lung adenocarcinoma.

Letaplimab (IBI188): Innovent Biologics
Letaplimab (IBI188) is a fully human IgG4 monoclonal antibody developed by Innovent Biologics that targets CD47, a "don't eat me" signal that inhibits macrophage-mediated phagocytosis. By blocking CD47, letaplimab enhances tumor cell clearance and activates T-cell responses. Preclinical studies confirmed its target specificity, mechanism, and antitumor efficacy. Phase 1a trials showed the drug was well tolerated up to the highest tested dose of 30 mg/kg weekly, with no dose-limiting toxicities.

Learn more about the novel and emerging lung adenocarcinoma pipeline therapies at https://www.delveinsight.com/report-store/lung-adenocarcinoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Lung Adenocarcinoma Therapeutics Assessment
By Product Type
• Mono
• Combination
• Mono/Combination.

By Stage
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

By Route of Administration
• Inhalation
• Inhalation/Intravenous/Oral
• Intranasal
• Intravenous
• Intravenous/ Subcutaneous
• NA
• Oral
• Oral/intranasal/subcutaneous
• Parenteral
• Subcutaneous

By Molecule Type
• Antibody
• Antisense oligonucleotides
• Immunotherapy
• Monoclonal antibody
• Peptides
• Protein
• Recombinant protein
• Small molecule
• Stem Cell
• Vaccine

Scope of the Lung Adenocarcinoma Pipeline Report
• Coverage: Global
• Key Lung Adenocarcinoma Companies: BerGenBio, Innovent Biologics, Lantern Pharma, Celltrion, Pionyr Immunotherapeutics, Onconova Therapeutics, Pfizer, Chugai Pharmaceutical, Novartis Oncology, Alaunos Therapeutics, Tmunity Therapeutics, Imugene Limited, Hoffmann-La Roche, Cantargia, and others.
• Key Lung Adenocarcinoma Pipeline Therapies: Belapectin, GXHPC 1, LPCN 1148, Cellgram-LC, BIV-201, Ornithine phenylacetate, CILO, TQA 3526, Saroglitazar, LDE225, Elafibranor, OP-724, BMS 986263, CNP-104, HTD 1801, ASC42, and others.

Dive deep into rich insights for drugs used for lung adenocarcinoma treatment, visit: https://www.delveinsight.com/report-store/lung-adenocarcinoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Table of Contents
1. Introduction
2. Executive Summary
3. Lung Adenocarcinoma Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Lung Adenocarcinoma Pipeline Therapeutics
6. Lung Adenocarcinoma Pipeline: Late-Stage Products (Phase III)
7. Lung Adenocarcinoma Pipeline: Mid-Stage Products (Phase II)
8. Lung Adenocarcinoma Pipeline: Early Stage Products (Phase I)
9. Therapeutic Assessment
10. Inactive Products
11. Company-University Collaborations (Licensing/Partnering) Analysis
12. Key Companies
13. Key Products
14. Unmet Needs
15. Market Drivers and Barriers
16. Future Perspectives and Conclusion
17. Analyst Views
18. Appendix

Contact Us:
Jatin Vimal
jvimal@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform, PharmDelve.

This release was published on openPR.